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Abstract
Background: A precise molecular genetic diagnosis has become the gold
standard for the correct identification and management of many inherited renal
diseases.
Methods: Here we describe a family with familial focal segmental
glomerulosclerosis, and include a clinical and patient perspective on the
diagnostic workup and relaying of genetic results following whole exome
sequencing.
Results: Through next generation sequencing approaches, we identified a
pathogenic mutation in  , the underlying cause of the phenotype. TheTRPC6
identification of this mutation had important clinical consequences for the
family, including allowing a living-unrelated kidney transplant to proceed in the
index case. There are also wider ranging social and ethical dilemmas
presented when reaching a genetic diagnosis like this one, which are explored
here by both physicians and the index case.
Conclusions: Through physician and patient perspectives in a family with
inherited renal failure we explore the implications and the magnitude of a
molecular genetic diagnosis.
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Introduction
Familial renal disease is a challenging problem, in terms of 
diagnosis, treatment and ethical decisions. Here we describe a 
family affected by a familial form of focal segmental glomerulo-
sclerosis (FSGS), which has resulted in end stage renal disease 
(ESRD) in two family members, with other family members at 
risk of the same disease. We wished to explore the significance of 
making a genetic diagnosis of familial ESRD and the impact of 
such a diagnosis on the index patient and their family. We there-
fore outline both the clinical and patient perspective of the index 
patient and her family.
Clinical case report
The index case presented in 2003 at the age of 30 years to renal 
services after her first pregnancy in 2003. She had developed 
heavy proteinuria and hypoalbuminemia during her pregnancy. 
After delivery of a healthy son at 40+2 weeks, her proteinuria 
reduced from a urine protein/creatinine ratio (uPCR) of 1200mg/
mmol to 350mg/mmol at 6 months post-partum (Figure 1A). 
Her serum creatinine and blood pressure values remained normal 
during this pregnancy.
A positive family history of renal disease was known (Figure 1B). 
The index case’s mother had presented similarly during her 
first pregnancy at age 30 in 1973. Her renal function stead-
ily declined despite commencement of an ACE inhibitor and 
she reached ESRD in 2015 at the age of 70 years, and was 
commenced on peritoneal dialysis. In addition, a maternal 
grandmother had died in her 60s of “renal disease” but the exact 
diagnosis was unknown. The index case also had two maternal 
aunts who are not known to have renal disease. At this stage, no 
other family members had presented with symptoms consistent 
with renal disease.
In 2004, due to persistent proteinuria, 10 months after her first 
pregnancy, the index patient underwent a renal biopsy, which dem-
onstrated FSGS. This was managed conservatively. At the age of 
32 years and with careful pre-conception counselling, our patient 
conceived her second child. Her proteinuria again increased dur-
ing this pregnancy. A healthy daughter was delivered successfully 
and post-partum, the proteinuria settled (uPCR = 650mg/mmol). 
During her third pregnancy aged 36, her proteinuria increased 
dramatically (uPCR = 1090mg/mmol at 20 weeks gestation and 
1340mg/mmol at 33 weeks’ gestation). This was associated with 
other features of nephrotic syndrome, including serum albumin of 
20g/L and estimated Glomerular Filtration Rate (eGFR) declining 
to 45ml/min/1.73m2 (Figure 1A). This prompted early delivery of 
her son at 36+5 weeks at a weight of 2.3kg, who then required a ten 
day stay at the specialist baby unit.
Following this third and final pregnancy, blood pressure was opti-
mised with a combination of angiotensin receptor blockers and 
thiazide diuretic within the renal clinic. Despite these measures, 
her eGFR continued to progressively decline (Figure 1A) and she 
received counselling and information regarding the various methods 
of renal replacement therapy, opting for peritoneal dialysis when 
required. Her husband offered to be a living-unrelated kidney donor 
and pre-emptive renal transplantation work-up was commenced.
Given the likelihood of familial FSGS leading to ESRD, based 
on renal histology and the clinical course of the index case and 
her mother, genetic studies were initiated, following informed 
consent from the index case and her mother. Targeted genetic 
studies excluded mutations in WT1 and NPHS2 genes, and this 
was followed by whole exome sequencing which identified a 
known pathogenic variant in TRPC6 (c.2683C>T; p.Arg895Cys) 
(Table 1), which segregated from the affected mother. The finding 
Figure 1. Clinical progression of index case and family pedigree. A. Clinical progression of index case over time with serum albumin (solid 
line), urine protein/creatinine ratio (dashed line) and estimated Glomerular Filtration Rate (eGFR). Pregnancies marked with shaded area (P). 
B. Family tree with index case arrowed. Males are squares, females are circles. Heterozygously affected individuals are semi-shaded. Sibling 
with proteinuria marked with “?”.
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of a genetic mutation causing FSGS meant that the likelihood of 
recurrence of FSGS in a non-related donor was low and her liv-
ing-unrelated transplant surgery was expedited. There have been no 
known recurrences of FSGS after renal transplants in patients with 
underlying mutations in TRPC61,2.
In 2014, at age 41, the index case received a pre-emptive living-
unrelated renal transplant from her husband, which had immediate 
graft function. Her transplant function remains excellent with no 
evidence of recurrent FSGS.
More recently, the index case’s brother was identified as having 
heavy proteinuria in 2016 at age 40, and is undergoing further 
investigations (Figure 1B). The three children of the index patient, 
who are fit and well, have not yet been tested for the disease caus-
ing variant.
Genetics and underlying mechanism of disease of 
familial FSGS
The first identification of human TRPC6 mutations was reported 
in 2005. Here, a point mutation in TRPC6 was identified in a 
family with autosomal dominant focal segmental glomeruloscle-
rosis1. Since then, several other mutations in TRPC6 have been 
described. The TRPC6 p.R895C heterozygous mutation that we 
report here has been described previously in a large Mexican 
family2. Here, 9 of 25 family members were affected and 
presented between the ages of 18 and 46 years, and 6 of the family 
members reached ESRD. Of these, 2 had received renal transplants 
with no evidence of recurrent disease. TRPC6 is a non-selective 
cation channel3 which is expressed in podocytes and glomerular 
endothelial cells2. TRPC6 channel activity at the slit diaphragm 
is required for the regulation of podocyte structure and function2. 
Biophysical analysis of the p.R895C mutant TRPC6 channel 
showed pathogenic changes in the current-voltage relationship 
which were suggestive of a gain-of-function2, which in vivo would 
be predicted to increase calcium influx. Interestingly, podocytes 
express other TRPC channels, including TRPC1, TRPC2 and 
TRPC5, and an overlap in function may account for the usual 
adult onset of glomerular disease. Another level of complexity 
is that TRPC6 may also form heterotetramers with other TRPC 
channels2. The fact that the p.R895C mutation causes a gain-of-
function means that selective TRPC6 inhibitors such as larixyl 
acetate may represent a pharmacological therapy for this form 
of FSGS4. More recently, a role for TRPC6 in renal fibrosis has 
been identified, which may spur on efforts for the clinical use of 
TRPC6 inhibition in other progressive renal diseases5.
Patient perspective
“Even though my mother had a history of renal disease, and I 
had presented with proteinuria during my first pregnancy, there 
had been no suggestion made to me, or present in my mind of a 
possible genetic renal condition. When following my biopsy in 
1999, I received a probable diagnosis of familial FSGS, it came 
as a huge shock, not only to hear I had FSGS, but also the rarer 
familiar form. Furthermore, knowing you have a rare chronic 
illness is one thing, but more significantly, I was devastated 
about what the future might hold for our children.
With this is mind, we began enquiries about how to find out which 
faulty gene had caused the FSGS and it was decided to undertake 
genetic tests including sequencing my whole exome. Whilst the 
result might not help in the short term, it would be useful in terms 
of being able to test other family members in the future.
I remember the consultant saying that finding the change in the 
faulty gene was like looking for 1 change in 6 billion pieces of 
genetic code and the expression ‘needle in a haystack’ was men-
tioned. Even after such detailed analysis I was told that the results 
are sometimes inconclusive. Not wanting to miss an opportunity, 
I flippantly mentioned screening for other faulty genes – by which 
I mean other non-renal conditions. I did not consider the possibil-
ity that our type of familial FSGS may be caused by more than 
one faulty gene and this is a serious and worrying consideration 
for patients waiting for the results of any genetic sequencing, 
notwithstanding the added complications it infers for future research 
and potential management or cure.
The screening process took a long time (over 6 months) and 
several clinic appointments passed before we received the results. 
Fortunately, the investigations were positive and as strange as 
it sounds, I was pleased to be told that I carried a variant in the 
TRPC6 gene. No other faulty genes were identified. My mother was 
extremely interested in the diagnosis given her condition has been 
termed “nephrotic syndrome” for thirty years but this was tempered 
by an ill-founded sense of guilt that she had passed on her condition 
to her daughter. This is an emotion I can identify with in terms of 
my own children.
Consequently, the excitement about a positive result naively 
produced a sense of hope about a potential innovation in the 
near future, given we had a precise genetic cause. TRPC6 encodes 
a calcium channel and based on current understanding the 
protein is expressed in the podocyte of the kidney, an area currently 
Table 1. In silico analysis of TRPC6 variant.
Gene Variant MutationTaster Evolutionary 
Conservation
SIFT ExAC 
database
PolyPhen-2 dbSNP Ref
TRPC6 
c.2683C>T 
p.Arg895Cys
Disease causing D. rerio Damaging Not found Probably 
Damaging
rs121434394 Reiser et al. 
2005
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undergoing a lot of research. Whilst the condition is extremely 
complex, this form of FSGS may well be a candidate for clinical 
trials aiming to modify the faulty channel.
As a patient, having something concrete to hold on to, such 
as the likely cause of our condition, provided some comfort and a 
sense of empowerment. Receiving the news that the cause of our 
FSGS was genetic meant it was much less likely for proteinuria 
to reoccur in a transplant, whereas the risk of recurrence is high 
in patients with other forms of FSGS. The prospect of immedi-
ate kidney rejection is daunting even without the added anxiety 
of the disease reoccurring and causing rejection, and having this 
information was an enormous relief for our family. In addition, 
awareness of this mutation now means that other family members 
(should the need arise) need only have a blood test rather than a 
kidney biopsy.
The sting in the tail, in our particular case, is that the pathogenic 
variant of TRPC6 remains a very rare cause of familial FSGS, 
with only a small amount of published reports for doctors to refer 
to. The rate of deterioration in kidney function has been very 
different in myself and my mother, whose renal replacement 
therapy began at 70 years of age. In 2016, my brother presented 
with proteinuria and mildly raised blood pressure, and is await-
ing the results of his genetic tests. He has two children and will 
no doubt have considered the possibility that they may also be 
vulnerable. We have all had unique experiences, and this does 
not make the analysis easier for the nephrologists, or give them the 
tools to predict future outcomes.
Identifying the variant in TRPC6 contributing to our form of 
familial FSGS, does however open up the opportunity to support 
directed research studies and help further the knowledge about 
this condition. At this stage, we have decided with the support of 
the nephrologists, not to test our children, and will do so when 
the time is right. Yet whilst the threat of this condition hangs over 
their heads, we continue to fundraise and support renal research 
in the hope that one day a cure may be found.”
Discussion and conclusions
Using a clinical case summary and a reflective patient perspective, 
we provide an example of how a molecular genetic diagnosis in a 
life threatening inherited renal disease may provide an explanation 
of the underlying disease process and offer the ability for screen-
ing of other family members without the need for invasive tests 
such as renal biopsy. A genetic diagnosis, by its very nature, also 
raises issues within the patient and their family members, which 
may be far reaching. Importantly, a genetic diagnosis often furthers 
our knowledge of disease phenotypes in rare inherited disorders, 
and hopefully provides momentum for future research into 
precision medicine therapies. Engagement of patients and their 
families in the importance and value of genetic and genomic data 
for diagnostic, therapeutic and prognostic use should be actively 
encouraged. Mainstreaming of genomic medicine into medical 
specialties such as nephrology needs to be embraced by patients 
and their physicians.
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The authors present the insidious course of an infrequent subtype of FSGS, the  -relatedTRPC6
glomerulopathy, that is an extremely rare renal disorder with ca.100 families diagnosed worldwide. Most
likely an individual nephrologist will see no more than one-two such cases during his/her years of practice.
The presented paper is an excellent source of information on how to comprehensively handle such
patients, not only from medical but also emotional and ethical perspective.  
The strong points of the work are 1) presenting the recent advances in diagnostics resulting from rapid
improvements in genetic sequencing technologies making kidney biopsy (almost) obsolete; 2) including
the patients perspective and highlighting their engagement not only in clinical management but also in
research .
The weak point is too superficial presentation of the current standards of preemptive genetic testing in
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testing in the entire family, but most of the family members were not subject to any genetic testing, the
affected grandmother included. Therefore, I recommend that the graph reports on phenotype and not
genotype, ie. the individuals with phenotype expressed should be marked as “fully filled-in” while the
information re: mutational status is to be provided below where available.
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Excellent case report highlighting an important area of genetic testing being very useful for managing the
patient. The report shows the importance of taking a family history in any disease especially renal and
exploring this further. Having the patient perspective adds a different angle which is very important for
doctors to be aware of as lots of learning can happen from this.
Is the background of the case’s history and progression described in sufficient detail?
Yes
Are enough details provided of any physical examination and diagnostic tests, treatment given
and outcomes?
Yes
Is sufficient discussion included of the importance of the findings and their relevance to future
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Familial cases of rare diseases provide a remarkable opportunity to delineate important biological
processes relevant to human disease. Of particular importance, are the implications for future therapeutic
strategies for refractory and progressive diseases such as focal segmental glomerulosclerosis. 
Iqbal and Sayer through their report elegantly present the natural history of TRPC6-associated
glomerulopathy arising as a result of the mutation c.2683C>T; p.Arg895Cys which concurs with previous
reports of disease manifestation of the same genotype by Reiser et al in 2005. Presentation tends to have
an insidious onset in mid-adulthood and despite intervention with ACEIs, patients with this genotype
progress towards end-stage renal disease. Functional characterisation of the TRPC6
variant, p.Arg895Cys, utilising electrophysiological studies, revealed the likelihood that this variant
represented a gain of function in the encoded mutant protein. Increased intracellular calcium influx as a
result of gain of function mutations in TRPC6 have been shown to lead to increased podocyte apoptosis,
a common pathogenetic mechanism of FSGS. Therefore,  downstream inhibition of increased TRPC6
activation, represents a therapeutic strategy for patients with TRPC6-associated glomerulopathy. As
highlighted by Iqbal and Sayer, without effective treatment for this disease, progression to end-stage renal
disease and renal transplantation occurs. For this particular variant, the risk of recurrence post renal
transplant is negligible.
Including the patient perspective is an innovative approach to the case reporting of interesting pedigrees
of rare disease. By undertaking such a strategy, Iqbal and Sayer highlight the importance of patient
engagement in genomics research by consent for testing of additional affected and unaffected family
members to fully characterise the genotype-specific disease manifestations. Furthermore, it provides an
answer for the affected patients and provides a rationale for clinical decisions relating to their care.
Importantly, this report also provided perspective with regards to future testing of prospective
asymptomatic younger family members and whether to burden families with advance knowledge of
prospective disease susceptibility.
What this knowledge does offer, of course, is the possibility to influence the disease course prior to
manifestation of overt disease symptoms and careful consideration of this prospect should be highlighted
at time of consent.
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it is of an acceptable scientific standard.
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doi:10.5256/f1000research.12212.r21847
   Moin A. Saleem
Children's Renal Unit and Academic Renal Unit, Bristol Children's Hospital, University of Bristol, Bristol,
UK
This is an interesting way of presenting a familial case of renal disease from the patient perspective. The
case illustrates how a new diagnosis of monogenic (Mendelian) disease can impact on the family, by
firstly clarifying the underlying cause, and being able to discuss in more detail the prognostic and genetic
testing implications.
It also illustrates the powerful impact of the rapid improvements in genetic sequencing technologies, and
how these have translated into clinical practice. It is worth emphasising that this will have impact on all
clinicians treating renal (and other) diseases, who will need to keep up to date with the current screening
technologies and interpretation/limitations of the data generated. In the UK routine whole genome
sequencing of patients with rare diseases is being rolled out, so there will be more cases like this being
uncovered and requiring counselling.
 
One key issue touched upon is the ethical implications of testing younger family members, who may (or
may not) develop disease much later in life. The consensus at the moment is to wait until the young
person is of an age to make the decision to test independently, unless there are treatment implications of
knowing earlier in life. With this particular mutation this is unlikely to be the case, though cases of TRPC6
mutations have been reported to present with proteinuria as early as 6 years of age.
Another ethical consideration of whole exome or genome sequencing is of finding completely unrelated
potentially pathogenic mutations. This needs careful pre-counselling before the test is done.
Is the background of the case’s history and progression described in sufficient detail?
Yes
Are enough details provided of any physical examination and diagnostic tests, treatment given
and outcomes?
Yes
Is sufficient discussion included of the importance of the findings and their relevance to future
understanding of disease processes, diagnosis or treatment?
Yes
Is the case presented with sufficient detail to be useful for other practitioners?
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 Is the case presented with sufficient detail to be useful for other practitioners?
Yes
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